Inclusion Criteria: 

• Male or female patients, age 18 years or older at the time of signing the informed consent form (ICF). If over the age of 65, patient must have a family history of CKD or clinical suspicion of genetic disorder.
• Able to read, understand, and provide written informed consent
• Willing and able to comply with the study-related procedures
• Diagnosis of kidney disease, and/or one of the following (note: can be newly diagnosed or existing patient):
  • Nephropathy associated with Diabetes Mellitus (DM)*;
  • Nephropathy associated with Hypertension*;
  • Cystic nephropathy*;
    • *Total number of patients in each of these categories will not exceed 10% of total cohort. This 10% is going to be measured by Natera (Sponsor) for the entire cohort and not per center/site.
  • Congenital nephropathy;
  • Tubulointerstitial disease of unknown etiology;
  • Proteinuric disease suggestive of a primary glomerulopathy;
  • Hematuria;
  • Early, severe or familial hypertension;
  • Thrombotic microangiopathy;
  • Electrolyte and/or acid base disorder;
  • Nephrolithiasis with family history;
  • CKD of unknown cause after standard nephrological evaluation;
  • End stage kidney disease (ESRD.

Exclusion Criteria:

• Age less than 18, or greater than 65, without a family history of CKD or clinical suspicion of genetic disorder.
• History of renal transplant.
• Clinical features and a kidney biopsy diagnosis strongly indicative of a secondary nephropathy (e.g., diabetic nephropathy, lupus nephritis, acute kidney injury).
• Previously confirmed diagnosis of a hereditary kidney disease via genetic testing.
• Received a blood transfusion within that last 30 days of study blood draw.

Eligibility last updated 9/8/22. Questions regarding updates should be directed to the study team contact.